Abstract 3291
Background
Microsatellite instability (MSI) is thought to be a marker of immunogenicity and better prognosis in colorectal cancer (CRC). However, the mechanism by which MSI confers a survival advantage is not well known and there is a range of results reported in the literature.
Methods
A systematic literature search of original studies was performed on Ovid searching Medline, Embase, Cochrane Library, CINAHL, Clinical Trials databases from inception of database to current. Data extracted included age, stage, MSI-H, MSS and MSI-L, proximal (right) vs. distal (left), colon vs. rectal, BRAF status, type of MSI or IHC test used, incidence of Lynch within cohort. The primary endpoint was survival (overall survival (OS), disease/relapse free survival (DFS) and disease (cancer) specific survival DSS). Statistical analysis was performed using RevMan Ver 5.3 Cochrane Collaboration.
Results
From 11,747 studies, 117 met the inclusion criteria (n = 100,257; MSI-H n = 12,263, (MSI-H 12.2%). Overall, MSI was associated with improved OS (OR 0.80 (0.71, 0.91). When stratified by stage, there was no difference in OS in stage I and IV, but a protective effect in stage II (OR 0.69 (0.51, 0.92)) and III (0.70 (0.54, 0.91)) CRC. By age, there was benefit in studies where reported median age < 60 (OR 0.66 (0.54,0.82)) but not ≥ 60. There was no difference in OS between MSI-L and MSS. In studies including only mucinous/signet cell/poor differentiation, there was no difference in OS. In both right and left colon, MSI status was associated with improved OS, but not in the rectum. MSI status was associated with improved DFS (HR 0.75 (0.66, 0.84)), but there was no difference in DSS (HR 0.78 (0.60, 1.03)), and this was seen in all stages (I-IV).
Conclusions
MSI is associated with improved overall survival in stage II and III colorectal cancer. Improved prognosis is seen in younger patients, in both right and left sided colon cancer, but evidence is limited in rectal cancer. MSI was associated with less relapse, but was not associated with cancer specific survival at any stage.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4317 - Prognostic factors analysis of 343 patients with adenocarcinoma of esophagogastric junction
Presenter: Yixun Lu
Session: Poster Display session 2
Resources:
Abstract
4099 - Effects of preoperative preparation time on efficacy of neoadjuvant chemotherapy (SOX) in patients with advanced gastric cancer
Presenter: Xinxin Wang
Session: Poster Display session 2
Resources:
Abstract
3769 - The prognostic value of higher absolute lymphocyte counts for patients with surgically resected non-advanced gastric cancer
Presenter: Se Jun Park
Session: Poster Display session 2
Resources:
Abstract
1718 - Trastuzumab and pertuzumab added to neoadjuvant chemoradiotherapy in resectable HER2+ esophageal adenocarcinoma patients: an update on survival and predictive biomarkers in the TRAP study
Presenter: Charlotte Stroes
Session: Poster Display session 2
Resources:
Abstract
5403 - Interim analysis of a phase II trial of perioperative chemotherapy plus avelumab in esophagogastric and gastric adenocarcinoma
Presenter: Thierry Alcindor
Session: Poster Display session 2
Resources:
Abstract
591 - Evaluation of the introduction of primary G-CSF prophylaxis to the FLOT chemotherapy regimen.
Presenter: Kelly-Marie Crampton
Session: Poster Display session 2
Resources:
Abstract
1402 - Subgroup analyses of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with 2 and 4 courses of cisplatin/S-1 (CS) and docetaxel/cisplatin/S-1 (DCS) as neoadjuvant chemotherapy for locally advanced gastric cancer
Presenter: Tsutomu Hayashi
Session: Poster Display session 2
Resources:
Abstract
3743 - HER2 Copy Number as Predictor of Disease-Free Survival in HER2-Positive Resectable Gastric Cancer
Presenter: Zimin Liu
Session: Poster Display session 2
Resources:
Abstract
2032 - Effect of neoadjuvant chemotherapy on the Programmed Death-1 pathway in esophageal and gastric cancer
Presenter: Maria Svensson
Session: Poster Display session 2
Resources:
Abstract
4304 - A user-friendly nomogram to predict relapse-free survival (RFS) in western patients with resected gastric cancer (GC)
Presenter: Massimiliano Salati
Session: Poster Display session 2
Resources:
Abstract